| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/29/2010 | WO2010085820A2 Tricyclic compounds as antagonists of prostaglandin d2 receptors |
| 07/29/2010 | WO2010085805A1 Methods for treating acute myocardial infarctions and associated disorders |
| 07/29/2010 | WO2010085570A1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| 07/29/2010 | WO2010085047A2 Solid pharmaceutical composition comprising amlodipine and losartan |
| 07/29/2010 | WO2010085027A1 Solid pharmaceutical composition comprising amlodipine and losartan with improved stability |
| 07/29/2010 | WO2010084999A1 Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| 07/29/2010 | WO2010084944A1 NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND |
| 07/29/2010 | WO2010084851A1 Peptide capable of binding to immunoglobulin |
| 07/29/2010 | WO2010084767A1 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
| 07/29/2010 | WO2010084661A1 Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound |
| 07/29/2010 | WO2010084512A1 Novel oxime derivatives |
| 07/29/2010 | WO2010084384A1 Combinations of an antiplatelet agent and an antioxidant for the treatment of vascular disorders |
| 07/29/2010 | WO2010084158A1 Anti-cd 160 monoclonal antibodies and uses thereof |
| 07/29/2010 | WO2010084121A1 Novel diaza-bicyclononyl-pyrimidinyl derivatives and their medical use |
| 07/29/2010 | WO2010083633A1 Compounds uesed for anti-hypertension, preparation methods, compositions and uses thereof |
| 07/29/2010 | WO2010083615A1 Compositions and methods for silencing apolipoprotein c-iii expression |
| 07/29/2010 | WO2010083611A1 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
| 07/29/2010 | WO2010060934A3 Cnnm proteins and uses thereof |
| 07/29/2010 | WO2010045582A3 Compositions and methods for treating or preventing hypoxic or ischemic injury |
| 07/29/2010 | WO2010042512A3 Detection of atherosclerosis using indocyanine green |
| 07/29/2010 | WO2010020307A3 Indazole-5-carboxylic acid hydrazide derivatives |
| 07/29/2010 | WO2010018549A3 Therapeutic compositions containing macitentan |
| 07/29/2010 | WO2009157018A3 Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof |
| 07/29/2010 | WO2009115658A9 Use of a caspase-1 inhibitor for treating atherosclerotic plaque |
| 07/29/2010 | US20100190964 Antibodies to human ErbB4 |
| 07/29/2010 | US20100190867 Stable and bioavailable compositions of isomers of lycopene for skin and hair |
| 07/29/2010 | US20100190852 Short acting phenylalkylamine calcium channel blockers and uses thereof |
| 07/29/2010 | US20100190840 Tissue specific gene therapy treatment |
| 07/29/2010 | US20100190838 Connective Tissue Growth Factor Fragments and Methods and Uses Thereof |
| 07/29/2010 | US20100190835 Pharmaceutical composition comprising aleglitazar |
| 07/29/2010 | US20100190830 (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives |
| 07/29/2010 | US20100190829 Renin inhibitors |
| 07/29/2010 | US20100190824 Novel Substituted Piperidones as HSP Inducers |
| 07/29/2010 | US20100190813 Spiro [piperidine-4- 4' -thieno [3,2-c] pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| 07/29/2010 | US20100190802 Carboxamide compounds and methods for using the same |
| 07/29/2010 | US20100190801 Triazolopyridine derivatives as inhibitors of lipases and phospholipases |
| 07/29/2010 | US20100190790 Sigma receptor inhibitors |
| 07/29/2010 | US20100190788 Amide derivatives as kinase inhitors |
| 07/29/2010 | US20100190783 Triazolone derivatives |
| 07/29/2010 | US20100190782 Compounds and methods of use |
| 07/29/2010 | US20100190781 Sigma receptor inhibitors |
| 07/29/2010 | US20100190780 Sigma receptor inhibitors |
| 07/29/2010 | US20100190773 Anti-Cytokine Heterocyclic Compounds |
| 07/29/2010 | US20100190770 Compositions and methods for inhibition of the jak pathway |
| 07/29/2010 | US20100190769 Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| 07/29/2010 | US20100190763 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| 07/29/2010 | US20100190761 Diphenyl substituted alkanes |
| 07/29/2010 | US20100190756 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS |
| 07/29/2010 | US20100190749 Benzoxazole kinase inhibitors and methods of use |
| 07/29/2010 | US20100190746 Quinazolinones as potassium channel modulators |
| 07/29/2010 | US20100190737 Compositions comprising inosine and orotic acid and methods of use thereof for the treatment of certain heart conditions and enhancement of work capacity |
| 07/29/2010 | US20100190731 Methods for treating acute myocardial infarctions and associated disorders |
| 07/29/2010 | US20100190722 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 07/29/2010 | US20100190718 Methods for preventing or treating mitochondrial permeability transition |
| 07/29/2010 | US20100190717 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| 07/29/2010 | US20100190716 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 07/29/2010 | US20100190713 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 07/29/2010 | US20100190712 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine |
| 07/29/2010 | US20100190711 Big gastrin i as a therapeutic agent |
| 07/29/2010 | US20100190703 Peptides specific for human blood outgrowth endothelial cells |
| 07/29/2010 | US20100190698 Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor |
| 07/29/2010 | US20100189830 Sweet Gum Fruit Extract as a Therapeutic Agent |
| 07/29/2010 | US20100189819 Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
| 07/29/2010 | US20100189785 Use of D-ribose for fatigued subjects |
| 07/29/2010 | US20100189770 Bioerodible patch |
| 07/29/2010 | US20100189720 Novel card proteins involved in cell death regulation |
| 07/29/2010 | US20100189704 Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose |
| 07/29/2010 | US20100189699 Method of constructing masses of myocardial cells and use of the myocardial cell mass |
| 07/29/2010 | US20100189697 Cardiac-specific progenitor cells |
| 07/29/2010 | US20100189695 Irak-1 as regulator of diseases and disorders |
| 07/29/2010 | US20100189686 Albumin Fusion Proteins |
| 07/29/2010 | US20100189682 Biologically active proteins having increased In Vivo and/or In Vitro stability |
| 07/29/2010 | US20100189646 Carbazole Derivatives as Functional 5-HT6 Ligands |
| 07/29/2010 | CA2788223A1 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
| 07/29/2010 | CA2750561A1 Compositions and methods for silencing apolipoprotein c-iii expression |
| 07/29/2010 | CA2750444A1 Anti-cd 160 monoclonal antibodies and uses thereof |
| 07/29/2010 | CA2750106A1 Poly (adp-ribose) polymerase (parp) inhibitors |
| 07/29/2010 | CA2749957A1 Solid pharmaceutical composition comprising amlodipine and losartan |
| 07/29/2010 | CA2749955A1 Solid pharmaceutical composition comprising amlodipine and losartan with improved stability |
| 07/29/2010 | CA2747801A1 N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
| 07/29/2010 | CA2747251A1 Methods for treating acute myocardial infarctions and associated disorders |
| 07/28/2010 | EP2210903A1 Anti-CD160 monoclonal antibodies and uses thereof |
| 07/28/2010 | EP2210888A2 Stable micronized candesartan cilexetil and methods for preparing thereof |
| 07/28/2010 | EP2210880A1 Benzoxazinone derivative |
| 07/28/2010 | EP2210872A1 New crystalline form III of agometalin, the process for its preparation and pharmaceutical compositions containing it |
| 07/28/2010 | EP2210622A1 Therapeutic agent for heart disease, which is intended to be used in cell transplantation therapy |
| 07/28/2010 | EP2210609A1 Agent for promoting the secretion of adiponectin and/or inhibiting the decrease in the secretion of adiponectin |
| 07/28/2010 | EP2210603A1 Pharmaceutical composition for inhibiting the accumulation of amyloid- b protein |
| 07/28/2010 | EP2210600A1 Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine |
| 07/28/2010 | EP2210092A2 Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
| 07/28/2010 | EP2209795A1 Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders |
| 07/28/2010 | EP2209761A1 Diphenyl substituted cycloalkanes |
| 07/28/2010 | EP2209376A1 Novel seh inhibitors and their use |
| 07/28/2010 | EP1954677B1 Thiomorpholine compound and process for preparing the same |
| 07/28/2010 | EP1458392B9 Acridones as inhibitors of impdh enzyme |
| 07/28/2010 | EP1369418B1 Quinazoline derivatives |
| 07/28/2010 | EP1315831B1 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 07/28/2010 | CN1972679B Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists |
| 07/28/2010 | CN1929845B Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| 07/28/2010 | CN1905875B The use of quaternary pyridinium salts as vasoprotective agents |